These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30872821)

  • 1. Tumour-agnostic drugs and future cancer treatment.
    Børset M
    Tidsskr Nor Laegeforen; 2019 Mar; 139(5):. PubMed ID: 30872821
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting tropomyosin receptor kinase for cancer therapy.
    Miao Q; Ma K; Chen D; Wu X; Jiang S
    Eur J Med Chem; 2019 Aug; 175():129-148. PubMed ID: 31077998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the right TRK: from oncogene discovery to cancer therapeutics.
    Barbacid M
    Ann Oncol; 2019 Nov; 30 Suppl 8(Suppl 8):viii3-viii4. PubMed ID: 32223936
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumour-agnostic drugs in paediatric cancers.
    Chisholm JC; Carceller F; Marshall LV
    Br J Cancer; 2020 May; 122(10):1425-1427. PubMed ID: 32161367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
    Costa DB
    J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391
    [No Abstract]   [Full Text] [Related]  

  • 6. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
    Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA
    Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
    Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
    J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmazie in unserer Zeit 5/2008].
    Dingermann T; Laufer S; Winckler T
    Pharm Unserer Zeit; 2008; 37(5):349. PubMed ID: 18729281
    [No Abstract]   [Full Text] [Related]  

  • 9. Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned.
    Hogervorst MA; van Hattem CC; Sonke GS; Mantel-Teeuwisse AK; Goettsch WG; Bloem LT
    Drug Discov Today; 2024 Jul; 29(7):104031. PubMed ID: 38796096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-agnostic biomarker-guided oncology drug development.
    Jørgensen JT
    Expert Rev Mol Diagn; 2020 Jun; 20(6):583-592. PubMed ID: 31813299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: Novel therapies for cancer: why dirty might be better.
    Fojo T
    Oncologist; 2008 Mar; 13(3):277-83. PubMed ID: 18378537
    [No Abstract]   [Full Text] [Related]  

  • 14. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Decade of Nilotinib and Dasatinib: From In Vitro Studies to First-Line Tyrosine Kinase Inhibitors.
    O'Hare T
    Cancer Res; 2016 Oct; 76(20):5911-5913. PubMed ID: 27742672
    [No Abstract]   [Full Text] [Related]  

  • 17. [ALK inhibitor].
    Sakamoto H
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):48-50. PubMed ID: 23842228
    [No Abstract]   [Full Text] [Related]  

  • 18. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Larotrectinib in NTRK-Rearranged Solid Tumors
    Wilson FH; Herbst RS
    Biochemistry; 2019 Mar; 58(12):1555-1557. PubMed ID: 30865435
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.